Evidence map›Paper›PMID 31497189›Full record

ArticleAmerican journal of translational research2019

Downregulation of lncRNA ITSN1-2 correlates with decreased disease risk and activity of rheumatoid arthritis (RA), and reduces RA fibroblast-like synoviocytes proliferation and inflammation via inhibiting NOD2/RIP2 signaling pathway.

Tao Yue, Xiaolei Fan, Zhanming Zhang, Zhaoyi Liu, Mengru Guo, Fengmin Bai, Xumin Gong, Chenxin Gao, Lianbo Xiao

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Role of RP11-83J16.1, a novel long non-coding RNA, in rheumatoid arthritis.American journal of translational research · 2020
    Article
  16. Review
  17. Antiarthritic and Antihyperalgesic Properties of Ethanolic Extract fromEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tao YueDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 200052, China.
Xiaolei FanDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 200052, China.
Zhanming ZhangDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 200052, China.
Zhaoyi LiuDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 200052, China.
Mengru GuoDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 200052, China.
Fengmin BaiDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 200052, China.
Xumin GongDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 200052, China.
Chenxin GaoDepartment of Orthopedics, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 200052, China.
Lianbo XiaoDepartment of Orthopedics, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 200052, China.
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the effect of lnc-ITSN1-2 knockdown on cell proliferation, apoptosis, inflammation and mRNA expression patterns in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS), and the correlation of its synovium tissue expression with disease risk, inflammatory cytokines and disease activity of RA. Control shRNA plasmids and lnc-ITSN1-2 shRNA plasmids were transfected into RA FLS, and then cell proliferation, apoptosis, inflammatory cytokines expressions were evaluated. Subsequently, mRNA sequencing and bioinformatics analyses were conducted, and rescue experiment of nucleotide-binding oligomerization domain 2 (NOD2) mRNA overexpression on alleviating the functions of lnc-ITSN1-2 was performed. Additionally, lnc-ITSN1-2 and NOD2 mRNA expressions in synovial tissue in 30 RA patients and 15 controls were measured. Lnc-ITSN1-2 expression was increased in RA FLS compared with normal FLS. Lnc-ITSN1-2 knockdown inhibited RA FLS proliferation and inflammation while promoted RA FLS apoptosis. mRNA sequencing and bioinformatics analyses revealed 144 upregulated and 98 downregulated genes by lnc-ITSN1-2 knockdown, which were enriched in regulating inflammatory responses and cytokines related pathways. NOD2 was selected for rescue experiment, which disclosed that upregulating NOD2 alleviated the effect of lnc-ITSN1-2 knockdown on cell proliferation, apoptosis and inflammation in RA FLS. In addition, synovial tissue lnc-ITSN1-2 positively associated with NOD2 mRNA, and both of them positively correlated with disease risk, inflammation and activity of RA. Downregulation of lnc-ITSN1-2 correlates with decreased disease risk and activity of RA, and reduces RA FLS proliferation and inflammation via regulating NOD2/RIP2 signaling pathway.

Indexed as

apoptosisfibroblast-like synoviocytesinflammationlnc-ITSN1-2NOD2proliferationRheumatoid arthritis

Identifiers

PMID31497189
PMCPMC6731396
OpenAlexW2990250806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.